3653 results for «414»
3653 results
Radial and distal radial artery access for PCI
19 May 2026 – From EuroPCR 2026
This session provides an in-depth evaluation of radial and distal radial artery access for PCI, including a 20-year trend analysis of clinical outcomes, feasibility studies on distal radial interventions, and comparative real-world experiences. It also features meta-analyses of randomized trials on access approaches and early findings...
Devices and strategies in calcified lesions
21 May 2026 – From EuroPCR 2026
Explore advanced devices and techniques for treating calcified coronary lesions in this session. Discussions include the use of Eximer laser coronary atherectomy, novel cutting balloons, outcomes of rotational atherectomy in tortuous vessels, atherectomy combined with drug-coated balloon therapy, and calcium fracture patterns following Shockwave intravascular lithotripsy.
Treatment for calcified coronary artery disease in the real world
19 May 2026 – From EuroPCR 2026
This session presents real-world experiences and evidence on treating calcified coronary artery disease. It includes meta-analyses comparing rotational atherectomy and balloon angioplasty, long-term outcomes of excimer laser atherectomy, and multicenter registry data on intravascular lithotripsy (IVL), particularly in diabetic and high-risk patients. The session also focuses...
Addressing difficult anatomy in STEMI patients
21 May 2026 – From EuroPCR 2026
This session addresses the challenges of managing difficult coronary anatomy in STEMI patients through a series of complex case studies. Topics include management of aneurysms, rare aorto-ostial lesions, thrombosis interplay, PPCI in dextrocardia situs inversus, and hybrid PCI approaches for multifaceted coronary issues.
TAVI complications: impact and improvement
20 May 2026 – From EuroPCR 2026
This session examines critical complications associated with TAVI and strategies to mitigate their impact. Topics include carbon-dioxide flushing to reduce brain injury, management of cardiac tamponade, AI-driven customization of TAVI in complex anatomies, and the influence of vascular complications on post-procedural quality of life.
INOCA/ANOCA: technical aspects
20 May 2026 – From EuroPCR 2026
This session covers technical aspects critical to the evaluation and management of ischemia with non-obstructive coronary arteries (INOCA) and angina with non-obstructive coronary arteries (ANOCA). Key topics include the impact of guide catheter shape, injection techniques for thermodilution measurements, advanced perfusion CMR diagnostics, and the physiological...
FFR and non-hyperaemic pressure ratios
20 May 2026 – From EuroPCR 2026
This session presents contemporary clinical applications of fractional flow reserve (FFR) and non-hyperaemic pressure ratios (NHPR), highlighting real-world impacts of physiology microcatheter-based indices, the interplay between epicardial stenosis and microvascular resistance, post-PCI hyperemia effects on iFR, and machine-learning driven outcome predictions.
Other right-sided and tricuspid valve interventions
20 May 2026 – From EuroPCR 2026
This session focuses on right-sided heart valve interventions, particularly targeting tricuspid valve disease. Topics include clinical outcomes in atrial functional tricuspid regurgitation, management in the context of left-sided valvular disease, treatment approaches for tricuspid valve endocarditis, and advances in transcatheter therapies and device placements.
Four-Year Outcomes from the EVOLUT Low Risk Trial
26 Oct 2023
Dejan Milasinovic provides his take on the EVOLUT Low Risk trial, presented by Michael I. Reardon at TCT Congress 2023. 4-year results reveal a continuing trend towards lower combined rates of all-cause mortality and disabling stroke with TAVI compared with surgical aortic valve replacement (SAVR)
Author
Innvolution Healthcare reports one-year findings from the ALCHEMY study evaluating Eternia in 1000 patients at EuroPCR 2026
27 May 2026
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)
01 Apr 2025
Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.
Author
Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.
Author
Cardiac biomarkers in patients with asymptomatic severe aortic stenosis: primary biomarker analysis from the EARLY TAVR Trial
01 Apr 2025
Elad Asher provides his take on the primary biomarker analysis from the EARLY TAVR Trial presented by Brian R. Lindman at ACC.25 in Chicago.
Author
